Skip to main content

Optimal Management of Older Patients with Atrial Fibrillation

Drugs & Aging volume 4, pages 184–193 (1994)Cite this article

Summary

Long term oral warfarin should be administered to elderly patients with atrial fibrillation who are at high risk for developing thromboembolic stroke and who have no contraindications to anticoagulant therapy. Oral aspirin (acetylsalicylic acid) 325mg daily may be given to elderly patients with chronic atrial fibrillation who have contraindications to anticoagulant therapy or who are not at high risk for developing thromboembolic stroke.

Management of atrial fibrillation includes treatment of the underlying disease and precipitating factors. If patients have paroxysmal atrial fibrillation with a very rapid ventricular rate associated with hypotension, severe left ventricular failure or chest pain due to myocardial ischaemia, immediate direct-current cardioversion should be performed. Intravenous verapamil, diltiazem or a β-blocker should be used for immediate slowing of a very rapid ventricular rate associated with atrial fibrillation.

If a rapid ventricular rate associated with atrial fibrillation persists at rest or during exercise despite digoxin, then oral verapamil, diltiazem or a β-blocker should be added. Low dosages of oral amiodarone (200 to 400 mg/day) may be used in selected patients with symptomatic life-threatening atrial fibrillation refractory to other therapy.

No medication which depresses atrioventricular conduction should be given to patients with atrial fibrillation and a slow ventricular rate. Cardioversion should not be performed in asymptomatic elderly patients with chronic atrial fibrillation.

This author would use a β-blocker for control of ventricular arrhythmias and following conversion of atrial fibrillation to sinus rhythm. Should atrial fibrillation recur, β-blockers have the additional advantage of slowing the ventricular rate.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  • Aronow WS. Correlation of arrhythmias and conduction defects on the resting electrocardiogram with new cardiac events in 1,153 elderly patients. American Journal of Noninvasive Cardiology 5: 88–90, 1991a

    Google Scholar 

  • Aronow WS. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment? Drugs & Aging 1: 98–103, 1991b

    Article  CAS  Google Scholar 

  • Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden death, total cardiac death, and total death in patients ≥ 62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. American Journal of Cardiology, in press, 1994

    Google Scholar 

  • Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. American Journal of Cardiology 63: 366–367, 1989

    PubMed  Article  CAS  Google Scholar 

  • Aronow WS, Koenigsberg M, Kronzon I, et al. Association of mitral annular calcium with new thromboembolic stroke and cardiac events at 39-month follow-up in elderly patients. American Journal of Cardiology 65: 1511–1512, 1990a

    PubMed  Article  CAS  Google Scholar 

  • Aronow WS, Landa D, Plasencia G, et al. Verapamil in atrial fibrillation and atrial flutter. Clinical Pharmacology and Therapeutics 26: 578–583, 1979a

    PubMed  CAS  Google Scholar 

  • Aronow WS, Mercando AD, Epstein S, et al. Effect of quinidine or procainamide versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in elderly patients with heart disease and complex ventricular arrhythmias. American Journal of Cardiology 66: 423–428, 1990b

    PubMed  Article  CAS  Google Scholar 

  • Aronow WS, Uyeyama RR. Treatment of arrhythmias with pindolol. Clinical Pharmacology and Therapeutics 13: 15–22, 1972

    PubMed  CAS  Google Scholar 

  • Aronow WS, Van Camp S, Turbow M, et al. Acebutolol in supra-ventricular arrhythmias. Clinical Pharmacology and Therapeutics 25: 149–153, 1979b

    PubMed  CAS  Google Scholar 

  • Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. New England Journal of Medicine 323: 1505–1511, 1990

    Article  Google Scholar 

  • Brand FN, Abbott RD, Kannel WB, et al. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. Journal of the American Medical Association 254: 3449–3453, 1985

    PubMed  Article  CAS  Google Scholar 

  • Cardiac Arrhythmia Suppression Trial. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New England Journal of Medicine 321: 406–412, 1989

    Article  Google Scholar 

  • Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. Journal of the American College of Cardiology 18: 345–355, 1991

    Article  Google Scholar 

  • Coplen SE, Antmann EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 82: 1106–1116, 1990

    PubMed  Article  CAS  Google Scholar 

  • Cox JL, Boineau JP, Schuessler RB, et al. Successful surgical treatment of atrial fibrillation. Review and clinical update. Journal of the American Medical Association 266: 1976–1980, 1991

    PubMed  Article  CAS  Google Scholar 

  • Danahy DT, Aronow WS. Propranolol and lidocaine. Clinical use as antiarrhythmic agents. Postgraduate Medicine 61: 113–117, 1977

    PubMed  CAS  Google Scholar 

  • David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. American Journal of Cardiology 44: 1378–1382, 1979

    PubMed  Article  CAS  Google Scholar 

  • Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. New England Journal of Medicine 327: 1406–1412, 1992

    PubMed  Article  CAS  Google Scholar 

  • Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Annals of Internal Medicine 117: 141–150, 1992

    PubMed  CAS  Google Scholar 

  • Falk RH, Knowlton AA, Bernard SA, et al. Digoxin for converting recent onset atrial fibrillation to sinus rhythm. A randomized, double-blinded trial. Annals of Internal Medicine 106: 503–506, 1987

    PubMed  CAS  Google Scholar 

  • Falk RH, Leavitt JI. Digoxin for atrial fibrillation: a drug whose time has gone? Annals of Internal Medicine 114: 573–575, 1991

    PubMed  CAS  Google Scholar 

  • Feld GK, Chen P-S, Nicod P, et al. Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs. American Journal of Cardiology 66: 378–383, 1990

    PubMed  Article  CAS  Google Scholar 

  • Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. Journal of the American College of Cardiology 20: 527–532, 1992

    PubMed  Article  CAS  Google Scholar 

  • Galun E, Flugelman MY, Glickson M, et al. Failure of long-term digitalization to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest 99: 1038–1040, 1991

    PubMed  Article  CAS  Google Scholar 

  • Gold RL, Haffajee CI, Charos G, et al. Amiodarone for refractory atrial fibrillation. American Journal of Cardiology 57: 124–127, 1986

    PubMed  Article  CAS  Google Scholar 

  • Jackman WM, Wang X, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. New England Journal of Medicine 324: 1605–1611, 1991

    PubMed  Article  CAS  Google Scholar 

  • Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 82: 1932–1939, 1990

    PubMed  Article  CAS  Google Scholar 

  • Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. A population-based study over three decades. New England Journal of Medicine 317: 669–614, 1987

    PubMed  Article  CAS  Google Scholar 

  • Lang R, Klein HD, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 83: 491–499, 1983

    PubMed  Article  CAS  Google Scholar 

  • Laupacis A, Albers G, Dunn M, et al. Antithrombotic therapy in atrial fibrillation. Chest 102 (Suppl.): 426S–433S, 1992

    PubMed  Article  CAS  Google Scholar 

  • Michelson EL. Clinical perspectives in management of Wolff-Parkinson-White syndrome. Part 2: Diagnostic evaluation and treatment strategies. Modern Concepts of Cardiovascular Disease 58: 49–54, 1989

    Google Scholar 

  • Morris Jr JJ, Peter RH, McIntosh HD. Electrical conversion of atrial fibrillation: immediate and long-term results and selection of patients. Annals of Internal Medicine 65: 216–231, 1966

    Google Scholar 

  • Murgatroyd FD, Xie B, Gibson SM, et al. The effects of digoxin in patients with paroxysmal atrial fibrillation: analysis of Holter data from the CRAFT-1 Trial. (Abstract). Journal of the American College of Cardiology 21: 203A, 1993

    Google Scholar 

  • Peterson P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1: 175–179, 1989

    Article  Google Scholar 

  • Peterson P, Kastrup J, Helweg-Larsen S, et al. Risk factors for thromboembolic complications in chronic atrial fibrillation. Archives of Internal Medicine 150: 819–821, 1990

    Article  Google Scholar 

  • Pollak A, Falk RH. Pacemaker therapy in patients with atrial fibrillation. American Heart Journal 125: 824–830, 1993

    PubMed  Article  CAS  Google Scholar 

  • Reimold SC, Cantillon CO, Friedman PL, et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. American Journal of Cardiology 71: 558–563, 1993

    PubMed  Article  CAS  Google Scholar 

  • Roth A, Harrison E, Mitani G, et al. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation 73: 316–324, 1986

    PubMed  Article  CAS  Google Scholar 

  • Salerno DM, Dias VC, Kleiger RE, et al. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. American Journal of Cardiology 63: 1046–1051, 1989

    PubMed  Article  CAS  Google Scholar 

  • Singer DE, Hughes RA, Gress DR, et al. Reply to Letter to the Editor by Aronow WS. New England Journal of Medicine 325: 130–131, 1991

    Google Scholar 

  • Stroke Prevention in Atrial Fibrillation Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. New England Journal of Medicine 322: 863–868, 1990

    Google Scholar 

  • Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 84: 527–539, 1991

    Article  Google Scholar 

  • Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Annals of Internal Medicine 116: 1–5, 1992a

    Google Scholar 

  • Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Annals of Internal Medicine 116: 6–12, 1992b

    Google Scholar 

  • Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22: 983–988, 1991

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Medical Director, Mount Sinai School of Medicine, Hebrew Hospital Home and the Department of Geriatrics and Adult Development, New York, New York, USA

    Wilbert S. Aronow

Authors
  1. Wilbert S. Aronow
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Aronow, W.S. Optimal Management of Older Patients with Atrial Fibrillation. Drugs & Aging 4, 184–193 (1994). https://doi.org/10.2165/00002512-199404030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199404030-00002

Keywords

  • Atrial Fibrillation
  • Stroke Prevention
  • Paroxysmal Atrial Fibrillation
  • Chronic Atrial Fibrillation
  • Encainide